Forte D, García-Fernández M, Sánchez-Aguilera A, Stavropoulou V, Fielding C, Martín-Pérez D, López JA, Costa ASH et al.(2020). Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy. Cell Metabolism vol. 32, (5) 829-843.e9.
Castelli R, Bergamaschini L, Teatini T, Cilumbriello L, Schiavon R, Gallipoli P, Deliliers GL(2020). Does Outcome/Survival of Patients With Myelodysplastic Syndromes Should Be Predicted by Reduced Levels of ADAMTS-13? Results From a Pilot Study. Clinical Lymphoma, Myeloma and Leukemia vol. 20, (8) e461-e467.
Horne GA, Stobo J, Kelly C, Mukhopadhyay A, Latif AL, Dixon-Hughes J, McMahon L, Cony-Makhoul P et al.(2020). A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. Leukemia vol. 34, (7) 1775-1786.
Sasca D, Yun H, Giotopoulos G, Szybinski J, Evan T, Wilson NK, Gerstung M, Gallipoli P et al.(2019). Cohesin-dependent regulation of gene expression during differentiation is lost in cohesin-mutated myeloid malignancies. Blood vol. 134, (24) 2195-2208.
Claudiani S, Metelli S, Kamvar R, Szydlo R, Khan A, Byrne J, Gallipoli P, Bulley SJ et al.(2019). Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML). Blood vol. 134, (1)
Yun H, Vohra S, Mupo A, Giotopoulos G, Sasca D, Horton SJ, Agrawal-Singh S, Meduri E et al. (2019). Mutational Synergy Coordinately Remodels Chromatin Accessibility, Enhancer Landscape and 3-Dimensional DNA Topology to Alter Gene Expression during Leukemia Induction. Blood. vol. 134, 278-278.
Basheer F, Giotopoulos G, Meduri E, Yun H, Mazan M, Sasca D, Gallipoli P, Marando L et al.(2019). Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML. Journal of Experimental Medicine vol. 216, (4) 966-981.
Castelli R, Gallipoli P, Schiavon R, Teatini T, Deliliers GL, Bergamaschini L(2019). Increased risk of heparin induced thrombocytopenia and thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. Journal of Thrombosis and Thrombolysis vol. 47, (1) 155-156.
Gallipoli P, Huntly BJP(2019). Prognostic models turn the heat(it)up on FLT3 <sup>ITD</sup> -mutated AML. Clinical Cancer Research vol. 25, (2) 460-462.
Gallipoli P, Huntly BJP(2019). Histone modifiers are oxygen sensors. Science vol. 363, (6432) 1148-1149.
Gallipoli P(2018). JAK of all trades: Ruxolitinib as a new therapeutic option for CML patients. Leukemia Research vol. 75, 71-72.
Tzelepis K, De Braekeleer E, Aspris D, Barbieri I, Vijayabaskar MS, Liu WH, Gozdecka M, Metzakopian E et al.(2018). SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4. Nature Communications vol. 9, (1)
Dickinson M, Kamdar M, Huntly BJP, Fernández De Larrea C, Cordoba R, Mateos M-V, Alegre A, Kim W-S et al. (2018). A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL). Blood. vol. 132, 1682-1682.
Gallipoli P, Huntly BJP(2018). Novel epigenetic therapies in hematological malignancies: Current status and beyond. Seminars in Cancer Biology vol. 51, 198-210.
Gallipoli P, Giotopoulos G, Tzelepis K, Costa ASH, Vohra S, Medina-Perez P, Basheer F, Marando L et al.(2018). Glutaminolysis is a metabolic dependency in FLT3 <sup>ITD</sup> acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition. Blood vol. 131, (15) 1639-1653.
Castelli R, Gallipoli P, Schiavon R, Teatini T, Deliliers GL, Bergamaschini L(2018). High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation. Journal of Thrombosis and Thrombolysis vol. 45, (1) 106-113.
Horton SJ, Giotopoulos G, Yun H, Vohra S, Sheppard O, Bashford-Rogers R, Rashid M, Clipson A et al. (2017). Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors. Nature Cell Biology. vol. 19, 1093-1104.
Gallipoli P, Costa AS, Tzelepis K, Giotopoulos G, Vohra S, Vassiliou G, Frezza C, Huntly B (2017). METABOLIC ADAPTATIONS TO TARGETED THERAPY IN FLT3 MUTATED ACUTE MYELOID LEUKAEMIA. HAEMATOLOGICA. vol. 102, 18-19.
Gallipoli P, Costa ASH, Vohra S, Castro C, Griffin J, Frezza C, Huntly B (2017). Metabolic adaptations to targeted therapy in FLT3 mutated acute myeloid leukaemia. The Lancet. vol. 389,
Tarafdar A, Hopcroft LE, Gallipoli P, Pellicano F, Cassels J, Hair A, Korfi K, Jørgensen HG et al.(2016). CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression. Blood
Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, Dovey OM, Mupo A, Grinkevich V et al.(2016). A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia. Cell Reports vol. 17, (4) 1193-1205.
Scott MT, Korfi K, Saffrey P, Hopcroft LE, Kinstrie R, Pellicano F, Guenther C, Gallipoli P et al.(2016). Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition. Cancer Discovery vol. 6, (11) 1248-1257.
Gidaro A, Deliliers GL, Gallipoli P, Arquati M, Wu MA, Castelli R(2016). Laboratory and clinical risk assessment to treat myelodysplatic syndromes. Clinical Chemistry and Laboratory Medicine vol. 54, (9) 1411-1426.
Giotopoulos G, Chan WI, Horton SJ, Ruau D, Gallipoli P, Fowler A, Crawley C, Papaemmanuil E et al.(2016). The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia. Oncogene vol. 35, (3) 279-289.
Castelli R, Gallipoli P, Gidaro A, Maddalena W, Arquati M, Lambertenghi Deliliers G (2015). Salvage Therapy with Bortezomib and Dexamethasone in Elderly Patients with Relapsed Refractory Multiple Myeloma. Blood. vol. 126, 5378-5378.
Castelli R, Pantaleo G, Gallipoli P, Gidaro A, Arquati M, Wu MA, Lambertenghi Deliliers G(2015). Salvage therapy with bortezomib and dexamethasone in elderly patients with relapsed/refractory multiple myeloma. Anti-Cancer Drugs vol. 26, (10) 1078-1082.
Giotopoulos G, van der Weyden L, Osaki H, Rust AG, Gallipoli P, Meduri E, Horton SJ, Chan WI et al.(2015). A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression. Journal of Experimental Medicine vol. 212, (10) 1551-1569.
Castelli R, Pantaleo G, Gallipoli P, Gallipoli P, Arquati M, Wu MA, Deliliers GL, Cicardi M (2015). SALVAGE THERAPY WITH BORTEZOMIB AND DEXAMETHASONE IN VERY ELDERLY PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA. HAEMATOLOGICA. vol. 100, 740-740.
Hopcroft LEM, Calderhead B, Gallipoli P, Holyoake TL, Girolami MA(2015). Bayesian inference for model selection: An application to aberrant signalling pathways in chronic myeloid leukaemia. Systems Genetics: Linking Genotypes and Phenotypes,
Gallipoli P, Giotopoulos G, Huntly BJP(2015). Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia. Therapeutic Advances in Hematology vol. 6, (3) 103-119.
Gallipoli P, Cook A, Rhodes S, Hopcroft L, Wheadon H, Whetton AD, Jørgensen HG, Bhatia R et al.(2014). JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34<sup>+</sup> cells in vitro and in vivo. Blood vol. 124, (9) 1492-1501.
Castelli R, Deliliers GL, Colombo R, Gallipoli P, Pantaleo G (2014). BIOSIMILAR EPOETIN IN ELDERLY PATIENTS WITH LOW-RISK/INTERMEDIATE 1 MYELODYSPLASTIC SYNDROMES IMPROVES ANEMIA, QUALITY OF LIFE AND BRAIN FUNCTION. HAEMATOLOGICA. vol. 99, 616-616.
Castelli R, Deliliers GL, Colombo R, Moreo G, Gallipoli P, Pantaleo G(2014). Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function. Annals of Hematology vol. 93, (9) 1523-1529.
Colombo R, Gallipoli P, Castelli R(2014). Thrombosis and hemostatic abnormalities in hematological malignancies. Clinical Lymphoma, Myeloma and Leukemia vol. 14, (6) 441-450.
Gallipoli P, Stobo J, Heaney N, Nicolini FE, Clark R, Wilson G, Tighe J, Mclintock L et al.(2013). Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up. British Journal of Haematology vol. 163, (5) 674-676.
Scott MT, Korfi K, Gallipoli P, Saffrey P, Jorgensen H, Cruz M, Hamilton A, Sinclair A et al. (2013). Misregulation Of The PRC2 Complex In CML Stem Cells Confers Sensitivity To An EZH2 Inhibitor. Blood. vol. 122, 2710-2710.
Giotopoulos G, Chan W-I, Ruau D, Gallipoli P, Fowler A, Göttgens B, Van Deursen J, Cole P et al.(2013). The Epigenetic Regulators CBP and p300 Facilitate Leukemogenesis and Represent Therapeutic Targets In Acute Myeloid Leukemia (AML). Blood vol. 122, (21) 3732-3732.
Chen M, Gallipoli P, Degeer D, Sloma I, Forrest DL, Chan M, Lai D, Jorgensen H et al.(2013). Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex. Journal of the National Cancer Institute vol. 105, (6) 405-423.
Mcilwaine L, Parker A, Sandilands G, Gallipoli P, Leach M(2013). Neutrophil-specific granule deficiency. British Journal of Haematology vol. 160, (6)
Gallipoli P, Pellicano F, Morrison H, Laidlaw K, Allan EK, Bhatia R, Copland M, Jørgensen HG et al.(2013). Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation. Blood vol. 122, (19) 3335-3339.
Jiang X, Chen M, Gallipoli P, Lai D, Ringrose A, Turhan A, Eaves C, Holyoake T (2012). 1009 Targeting Chronic Myeloid Leukemia Stem/progenitor Cells by Effective Inhibition of a Novel AHI-1-BCR-ABL-JAK2 Interaction Complex. European Journal of Cancer. vol. 48,
Gallipoli P, Jorgensen H, Holyoake T (2012). Modulation of TGF-beta 1 induced quiescence to selectively eradicate chronic myeloid leukaemia stem cells. BRITISH JOURNAL OF HAEMATOLOGY. vol. 157, 55-56.
Shah M, Gallipoli P, Lyons J, Holyoake T, Jørgensen H(2012). Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro. Blood Cells, Molecules, and Diseases vol. 48, (3) 199-201.
Gallipoli P, Abraham SA, Holyoake TL(2011). Hurdles Toward a Cure for CML: The CML Stem Cell. Hematology/Oncology Clinics of North America vol. 25, (5) 951-966.
Gallipoli P, Shepherd P, Irvine D, Drummond M, Holyoake T(2011). Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: Results from a West of Scotland and Lothian population study. British Journal of Haematology vol. 155, (1) 128-130.
Chen M, Gallipoli P, DeGeer D, Sloma I, Chan M, Lai D, Jorgensen H, Forrest D et al. (2011). TARGETING A NOVEL AHI-1-BCR-ABL-JAK2 INTERACTION COMPLEX BY COMBINATION TREATMENT WITH ABL AND JAK2 INHIBITORS IS EFFECTIVE AGAINST CML PATIENTS'S LEUKEMIC STEM/PROGENITOR CELLS IN VITRO AND IN VIVO. EXPERIMENTAL HEMATOLOGY. vol. 39, S18-S18.
DeGeer D, Gallipoli P, Chen M, Sloma I, Jorgensen H, Forrest D, Lambie K, Nakamoto H et al. (2010). Combined Targeting of BCR-ABL and JAK2 with ABL and JAK2 Inhibitors Is Effective Against CML Patients' Leukemic Stem/Progenitor Cells. BLOOD. vol. 116, 1393-1394.
DeGeer D, Gallipoli P, Chen M, Sloma I, Jorgensen H, Forrest D, Lambie K, Nakamoto H et al.(2010). Combined Targeting of BCR-ABL and JAK2 with ABL and JAK2 Inhibitors Is Effective Against CML Patients' Leukemic Stem/Progenitor Cells. Blood vol. 116, (21) 3404-3404.
O'Mahony O, McKay P, Gallipoli P, Jackson R (2010). A Review of Lymphoma in Non-transplant Patients on Immunosuppressive Therapy. JOURNAL OF PATHOLOGY. vol. 222, S26-S26.
Gallipoli P, Shepherd P, Mitchell L, Drummond M, Holyoake T (2010). RETROSPECTIVE ANALYSIS OF PROGNOSTIC FACTORS AND OUTCOME IN AN IMATINIB TREATED CML POPULATION FROM WEST OF SCOTLAND AND LOTHIAN. HAEMATOLOGICA. vol. 95, 342-342.
Gallipoli P, Shepherd P, Mitchell L, Drummond M, Holyoake T (2010). RETROSPECTIVE ANALYSIS OF PROGNOSTIC FACTORS AND OUTCOME IN AN IMATINIB TREATED CML POPULATION FROM WEST OF SCOTLAND AND LOTHIAN. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. vol. 95, 342-342.
Gallipoli P, Shepherd P, Eynaud P, Hughes M, Laird J, Rhodes S, Sefcick A, Stark A et al. (2010). Imatinib efficacy and tolerability in a 'real world' CML population study: Results from a West of Scotland and Lothian retrospective survey. BRITISH JOURNAL OF HAEMATOLOGY. vol. 149, 82-82.
Leitch C, Shah M, Gallipoli P, Zhou P, Yule M, Holyoake TL, Jorgensen HG (2010). JAK2 is a relevant target in chronic myeloid leukaemia. BRITISH JOURNAL OF HAEMATOLOGY. vol. 149, 77-77.
Hamilton A, Gallipoli P, Nicholson E, Holyoake TL(2010). Targeted therapy in haematological malignancies. Journal of Pathology vol. 220, (4) 404-418.
Gallipoli P, Clark A, Leach M(2009). The evolving management of a rare lymphoproliferative disorder-T-cell prolymphocytic leukemia. American Journal of Hematology vol. 84, (11) 750-753.
Gallipoli P, Tang A, Leach M(2009). Cortical blindness due to sagittal sinus thrombosis in acute lymphoblastic leukaemia. British Journal of Haematology vol. 145, (3)
Gallipoli P, Drummond M, Leach M(2009). Hemophagocytosis and relapsed peripheral T-cell lymphoma. European Journal of Haematology vol. 82, (3)
Fyfe AJ, Gallipoli P(2009). Multiple splenic calcifications: Images in haematology. British Journal of Haematology vol. 144, (6)
Gallipoli P(2009). Pseudotumour cerebri as a manageable side effect of prolonged all-trans retinoic acid therapy in an adult patient with acute promyelocytic leukaemia. European Journal of Haematology vol. 82, (3) 242-243.
Gallipoli P, McKay P, Jackson B, Gangopadhyay M, Leach M (2008). EXPERIENCE OF EXTRANODAL NK/T CELL LYMPHOMAS IN THE WEST OF SCOTLAND. HAEMATOLOGICA. vol. 93, 546-546.
Gallipoli P, McKay P, Jackson B, Gangopadhyay M, Leach M (2008). EXPERIENCE OF EXTRANODAL NK/T CELL LYMPHOMAS IN THE WEST OF SCOTLAND. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. vol. 93, 546-546.
Gallipoli P, Leach M(2007). Gingival infiltration in acute monoblastic leukaemia. British Dental Journal vol. 203, (9) 507-509.
Gallipoli P, Jones B, McQuaker IG, Parker AN (2007). Hickman line removal is succesfull in treating most of the septic episodes secondary to rhodoturula fungaemia in immunocompromised haemato-oncology patients. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. vol. 92, 227-228.
Gallipoli P, Robertson M, Tait RC (2007). Off-label use of rFVIIa and its clinical effectiveness: Results from a Scottish national audit. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. vol. 92, 31-32.
Gallipoli P, Robertson M, Tait RC (2007). Off-label use of rFVIIa and its clinical effectiveness: results from a Scottish national audit. BRITISH JOURNAL OF HAEMATOLOGY. vol. 137, 85-85.
Gallipoli P, Jones B, McQuaker IG, Parker A (2007). Risk factors, management and consequences of rhodoturula infections in immunocompromised haematology patients. BRITISH JOURNAL OF HAEMATOLOGY. vol. 137, 77-77.
Finelli C, Gallipoli P, Celentano E, Cacace G, Saldalamacchia G, De Caprio C, Contaldo F, Pasanisi F(2006). Assessment of physical activity in an outpatient obesity clinic in southern Italy: Results from a standardized questionnaire. Nutrition, Metabolism and Cardiovascular Diseases vol. 16, (3) 168-173.
Gallipoli P(2002). Glasgow: a very interesting place. The BMJ vol. 324, (Suppl S2)
Gallipoli P(2002). Medical education: Britain versus Italy. The BMJ vol. 324, (Suppl S2)
Clark JA, Deutch AY, Gallipoli PZ, Amara SG(1992). Functional expression and CNS distribution of a β-alanine-sensitive neuronal GABA transporter. Neuron vol. 9, (2) 337-348.